Primary Hyperoxaluria Type 1
At a Glance
Primary Hyperoxaluria Type 1 is a rare genetic condition in which a liver enzyme deficiency causes the body to overproduce oxalate, leading to recurrent kidney stones, kidney damage, and potentially widespread deposit of crystals in other organs.
This rare condition affects approximately one to three people per million and can present at any age, though symptoms most commonly appear during childhood or adolescence.
It is a chronic, progressive disease that requires lifelong management to prevent severe kidney damage and systemic complications.
While the condition was historically associated with a shortened life expectancy due to kidney failure, modern treatments have significantly improved the outlook and quality of life for many patients.
How It Affects You
Primary Hyperoxaluria Type 1 is a rare genetic disorder caused by a liver enzyme deficiency that leads to the overproduction of a substance called oxalate. Because the body cannot properly break down this excess oxalate, it must be filtered by the kidneys, where it combines with calcium to form hard crystals and stones. Over time, this process causes severe damage to the kidneys and urinary tract. If kidney function declines, oxalate can no longer be filtered out effectively and begins to build up in other tissues throughout the body, a condition known as systemic oxalosis. This widespread accumulation can lead to serious complications in various organs, including:
- Bones and joints, causing pain and increased fracture risk
- The heart, potentially affecting its rhythm and function
- The eyes, nerves, and skin
Causes and Risk Factors
Underlying Biological Mechanisms
Primary Hyperoxaluria Type 1 (PH1) is caused by a defect in the AGXT gene. This gene provides instructions for making an enzyme called alanine-glyoxylate aminotransferase (AGT), which is found in the liver. Normally, this enzyme helps convert a compound called glyoxylate into glycine. In people with PH1, the enzyme is either missing or does not work correctly. As a result, glyoxylate is converted instead into oxalate. The body cannot break down oxalate, so it must be removed through the kidneys. When the amount of oxalate is too high, it combines with calcium in the urine to form calcium oxalate crystals. These crystals form hard kidney stones and can deposit into the kidney tissue itself, a process called nephrocalcinosis.
Genetic Contributors
PH1 is an inherited disorder following an autosomal recessive pattern. This means a child must inherit two copies of the non-working gene, one from each parent, to develop the condition. Parents who each carry one copy of the mutated gene are known as carriers; they typically do not show symptoms of the disease but have a 25% chance of passing the condition to their child with each pregnancy. It is the most common and typically the most severe form of primary hyperoxaluria.
Prevention and Risk Reduction
Because PH1 is a genetic disorder, primary prevention of the underlying defect is not currently possible. However, for families with a known history of the condition, genetic counseling and testing can help assess the risk for future children. Secondary prevention strategies are critical for those diagnosed with the condition to slow disease progression. These include drinking large amounts of water to dilute urine and taking specific medications prescribed by a doctor to reduce oxalate production or crystallization. Early diagnosis is the most effective way to prevent permanent kidney damage.
Diagnosis, Signs, and Symptoms
Signs and Symptoms
The symptoms of Primary Hyperoxaluria Type 1 vary widely in severity and age of onset. The most common early sign is the formation of kidney stones, which can cause severe back or flank pain, blood in the urine, and painful urination. In infants, the condition may present as failure to thrive, poor feeding, or reduced urine output due to early kidney failure. Some individuals may develop urinary tract infections frequently. As the disease progresses, calcium oxalate crystals may deposit in the kidney tissue (nephrocalcinosis), leading to reduced kidney function. If the kidneys fail, oxalate builds up in the blood and deposits elsewhere in the body (systemic oxalosis), causing bone pain, vision problems, skin ulcers, heart conduction issues, and anemia.
Diagnostic Tests
Clinicians use several tools to identify PH1. Initial testing often involves a 24-hour urine collection to measure oxalate levels, which are typically very high in affected individuals. Blood tests may be used to measure plasma oxalate and check kidney function. A definitive diagnosis is confirmed through genetic testing to identify mutations in the AGXT gene. In rare cases where genetic results are inconclusive, a liver biopsy may be performed to measure enzyme activity, though this is less common today. Imaging tests like ultrasounds or CT scans are used to detect kidney stones and calcium deposits within the kidneys.
Differential Diagnosis
PH1 is often confused with other causes of kidney stones. It must be distinguished from Primary Hyperoxaluria Types 2 and 3, which are caused by different gene mutations and generally follow a different clinical course. It is also distinct from secondary hyperoxaluria, which is caused by dietary factors or intestinal disorders (such as Crohn's disease) that increase oxalate absorption from food, rather than internal overproduction.
Treatment and Management
Medications and Therapeutics
Management of Primary Hyperoxaluria Type 1 has advanced significantly. Standard treatment often includes Vitamin B6 (pyridoxine), which can reduce oxalate production in about 30% of patients who have specific gene mutations. Oral medications containing citrate (such as potassium citrate) are frequently prescribed to stop crystals from forming in the urine. Recently, newer RNA interference (RNAi) therapies, such as lumasiran and nedosiran, have been approved. These medications target specific liver enzymes to substantially lower the body's production of oxalate, treating the underlying metabolic issue rather than just the symptoms.
Lifestyle and Self-Care
The cornerstone of daily management is hyper-hydration. Patients must drink very large amounts of fluid (often 3 liters or more per square meter of body surface area per day) spread throughout the day and night to keep urine dilute and prevent stone formation. While dietary oxalate restriction is less effective for PH1 than for other stone formers (because the liver produces the oxalate internally), avoiding extremely high-oxalate foods like spinach and rhubarb is typically recommended as a sensible precaution.
Advanced Procedures
For patients with significant kidney stones, urological procedures like shock wave lithotripsy or ureteroscopy may be needed to remove stones. If kidney failure occurs, standard dialysis is often insufficient to clear the high load of oxalate. Intensive dialysis regimens are often required. The definitive cure for the metabolic defect is a liver transplant (which replaces the missing enzyme) combined with a kidney transplant (to replace the damaged organ). With the advent of new RNAi therapies, the need for liver transplantation may decrease for some patients.
When to See a Doctor
Patients should seek medical care if they experience symptoms of a kidney stone, such as sharp pain in the back or side, nausea, or blood in the urine. Emergency care is necessary if there is severe pain that is not relieved by medication, inability to urinate, or signs of infection like fever and chills. Routine follow-up with a nephrologist is essential to monitor kidney function and oxalate levels.
Severity and Prognosis
Severity and Disease Course
Primary Hyperoxaluria Type 1 is considered a serious condition. The severity can range from a severe infantile form that leads to kidney failure in early childhood to a milder form that presents with occasional stones in adulthood. Factors influencing severity include the specific genetic mutation and how early the condition is diagnosed. Without effective treatment, the constant formation of crystals damages the kidneys, leading to chronic kidney disease. Once the kidneys lose their ability to filter, the condition becomes life-threatening due to systemic oxalosis.
Prognosis and Long-Term Effects
Historically, the prognosis was poor for those with early-onset disease, often leading to End-Stage Renal Disease (ESRD) within the first few decades of life. However, modern treatments, particularly RNAi therapies, have fundamentally changed the outlook by preventing the production of oxalate. If treated early and effectively, many patients can preserve kidney function and lead active lives. Systemic oxalosis, if it occurs, can cause long-term complications like bone fractures, heart rhythm problems, and vision loss, but these are preventable with optimal management. Prognosis is best when the disease is identified before significant kidney damage has occurred.
Impact on Daily Life
Daily Activities and Coping
Living with PH1 requires constant attention to fluid intake, which can be disruptive to work, school, and sleep. Patients often need to wake up during the night to drink water and may need access to restrooms frequently. This
Common Questions and Answers
Q: Is Primary Hyperoxaluria Type 1 the same as having regular kidney stones?
A: No. While both conditions involve kidney stones, PH1 is a rare genetic disorder where the liver produces excessive oxalate internally. "Regular" stones are often caused by diet or dehydration. PH1 is much more serious and can lead to kidney failure and damage to other organs if not treated aggressively.
Q: Can I fix this condition by changing my diet?
A: Diet alone cannot fix PH1. Unlike other forms of hyperoxaluria where oxalate comes from food, in PH1 the liver produces the oxalate. While avoiding extremely high-oxalate foods is healthy, the main treatments involve medication and high fluid intake to manage the body's internal production.
Q: Is there a cure for PH1?
A: A liver transplant can effectively cure the metabolic defect because it provides the missing enzyme. However, this is a major surgery. New medications are now available that can manage the condition very effectively without surgery for many people.
Q: Will my children have this condition?
A: PH1 is an autosomal recessive disorder. If you have PH1, your children will be carriers (if your partner does not carry the gene). If your partner is also a carrier, there is a chance your children could have the disease. Genetic counseling is recommended to understand specific risks.
Q: How much water do I really need to drink?
A: Fluid intake is critical. Doctors typically recommend drinking enough to produce a high volume of urine every day, which often means drinking significantly more than the average person—sometimes 3 liters or more daily. It is important to follow the specific volume targets set by your specialist.